Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 4/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6285958 | 1.00 | PREP (0.65) | PREPMEN1NPC1RAB9AKMT2A | |
| SCHEMBL10339417 | 0.97 | PREP (0.65) | PREPMEN1NPC1RAB9AKMT2A | |
| SCHEMBL9501704 | 0.88 | PREP (0.53) | PREP | |
| SCHEMBL5741652 | 0.87 | MEN1 (0.63) | MEN1NPC1RAB9AKMT2A | |
| SCHEMBL7330019 | 0.87 | MEN1 (0.63) | MEN1NPC1RAB9AKMT2A | |
| SCHEMBL5741647 | 0.87 | MEN1 (0.63) | MEN1NPC1RAB9AKMT2A | |
| SCHEMBL8152361 | 0.86 | PREP (0.64) | PREPMEN1NPC1RAB9AKMT2A | |
| SCHEMBL8159989 | 0.86 | PREP (0.64) | PREPMEN1NPC1RAB9AKMT2A | |
| SCHEMBL8153245 | 0.84 | MEN1 (0.55) | PREPMEN1NPC1RAB9AKMT2A | |
| SCHEMBL8153242 | 0.84 | MEN1 (0.55) | PREPMEN1NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2905032-B1 | METHOD AND PHARMACEUTICAL COMPOSITION FOR INHIBITING PI3K/AKT/MTOR SIGNAL PATH | TARGETED THERAPEUTICS LLC (US) | 2018-09-05 | — | — | EP | disclosed |
| US-9750728-B2 | Method and pharmaceutical composition for inhibiting PI3K/AKT/mTOR signaling pathway | TARGETED THERAPEUTICS, LLC (US) | 2017-09-05 | — | — | US | disclosed |
| US-20170119747-A1 | METHOD AND PHARMACEUTICAL COMPOSITION FOR INHIBITING PI3K/AKT/MTOR SIGNALING PATHWAY | TARGETED THERAPEUTICS, LLC | 2017-05-04 | — | — | US | disclosed |
| US-9545396-B2 | Method and pharmaceutical composition for inhibiting PI3K/AKT/mTOR signaling pathway | TARGETED THERAPEUTICS, LLC (US) | 2017-01-17 | — | — | US | disclosed |
| US-20150328197-A1 | METHOD AND PHARMACEUTICAL COMPOSITION FOR INHIBITING PI3K/AKT/MTOR SIGNALING PATHWAY | TARGETED THERAPEUTICS, LLC (US) | 2015-11-19 | — | — | US | disclosed |
| EP-2905032-A1 | METHOD AND PHARMACEUTICAL COMPOSITION FOR INHIBITING PI3K/AKT/MTOR SIGNAL PATH | Targeted Therapeutics, LLC (US) | 2015-08-12 | — | — | EP | disclosed |
| CN-103705925-A | Pharmaceutical combinations and methods for inhibiting PI3K/AKT/mTOR signaling pathway | DUAN LEI | 2014-04-09 | — | — | CN | disclosed |
| US-6900238-B1 | HIV protease inhibitors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2005-05-31 | — | — | US | disclosed |
| EP-0873519-A4 | HIV PROTEASE INHIBITORS | SCRIPPS RESEARCH INST (US) | 2005-04-27 | — | — | EP | disclosed |
| EP-0861246-B1 | PROLYL ENDOPEPTIDASE INHIBITORS, THEIR PREPARATION AND THEIR PHARMACEUTICAL USE | SANDOR ERDOE DR (HU) | 2003-10-15 | — | — | EP | disclosed |
| WO-1998035960-A1 | PROLYLENDOPEPTIDASE INHIBITORS | Chinoin Gyógyszer és Vegyészeti Termékek Gyára Rt. (HU) | 1998-08-20 | — | — | WO | disclosed |
| WO-1997021100-A9 | HIV PROTEASE INHIBITORS | — | 1997-10-30 | — | — | WO | disclosed |
| WO-1997021100-A1 | HIV PROTEASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1997-06-12 | — | — | WO | disclosed |
| WO-1997007116-A1 | PROLYLENDOPEPTIDASE INHIBITORS | CHINOIN GYÓGYSZER ÉS VEGYÉSZETI (HU) | 1997-02-27 | — | — | WO | disclosed |
| EP-0754454-A1 | CHOLINESTERASE ACTIVATOR | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 1997-01-22 | — | — | EP | disclosed |
| US-5547978-A | ENDOPEPTIDASE INHIBITORS | MEIJI SEIKA KAISHA, LTD. (JP) | 1996-08-20 | — | — | US | disclosed |
| EP-0232849-B1 | PYRROLIDINEAMIDE DERIVATIVE OF ACYLAMINO ACID, PHARMACEUTICAL COMPOSITION AND USE | SUNTORY LIMITED (JP) | 1993-05-05 | — | — | EP | disclosed |
| US-5198458-A | Pyrrolidineamide derivatives of acylamino acid and pharmaceutical composition containing the same | SUNTORY LIMITED (JP) | 1993-03-30 | — | — | US | disclosed |
| US-4826870-A | CURING AMNESIA | SUNTORY LIMITED (JP) | 1989-05-02 | — | — | US | disclosed |
| EP-0232849-A2 | Pyrrolidineamide derivative of acylamino acid, pharmaceutical composition and use | SUNTORY LIMITED (JP) | 1987-08-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170119747-A1 | METHOD AND PHARMACEUTICAL COMPOSITION FOR INHIBITING PI3K/AKT/MTOR SIGNALING PATHWAY | MTOR, MAPKAP1, RICTOR | PREP 110/4885MEN1 235/4885NPC1 1366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.